Early Assessment of Efficacy and Safety of Biologics in Pediatric Allergic Diseases: Preliminary Results from a Prospective Real-World Study.

Lucia CaminitiFrancesca Galletta Simone Foti RandazzesePaolo BarracoStefano Passanisi Antonella GambadauroGiuseppe CrisafulliMariella ValenziseSara Manti

Published in: Children (Basel, Switzerland) (2024)

Our findings validate omalizumab and dupilumab as effective and safe therapeutic options for managing moderate-to-severe allergic diseases in children and adolescents.

Keyphrases

atopic dermatitis
allergic rhinitis
early onset
high intensity
young adults